Find the Perfect Plan for Your Investment Journey
T
Latest price
52 Week Range
A$14.42 - A$31.97
Next Earnings Date
Aug 20 2025 (Estimate)
Next Earnings Date
Aug 20 2025 (Est.)
Latest price
Market Cap | A$9.65B |
EV | A$9.52B |
Shares Outstanding | 353.77M |
Beta | 2.49 |
Analyst Rating | BUY |
Analyst Target Price | A$32.40 |
P/E 2025E | 66.49x |
P/Revenue 2025E | 7.50x |
Revenue | 368.90% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Revenue | 35.40% |
EPS | 72.00% |
Operating Cash Flow | 94.10% |
Free Cash Flow | 115.70% |
Gross Margin 2025E | 62.82% |
Net Profit Margin 2025E | 11.79% |
ROE 2025E | 20.60% |
ROCE 2024 | 13.92% |
DPS 2025E | A$0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
T
Telix Pharmaceuticals Limited
TLX
Sector
Healthcare
Industry
Biotechnology
CEO
Behrenbruch, Christian
Employees
423
Website
telixpharma.comIPO Date
2017-11-14
Headquarters
55 Flemington Road, Suite 401, North Melbourne, Victoria, 3051, Australia
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved